Eledon Advances Tegoprubart in Transplant Therapies, Sets Phase 3 Kidney Trial for Late 2026 — Eledon Pharmaceuticals, Inc.

Event summary

Eledon submitted an IND for a registrational islet cell transplantation study using tegoprubart in type 1 diabetes patients.
First patients enrolled in investigator-initiated studies for tegoprubart in islet cell and kidney transplants.
Company reaffirmed plans to initiate Phase 3 LEGACY kidney transplantation trial in Q4 2026.
Compassionate use of tegoprubart expanded to highly sensitized kidney transplant patients and those with calcineurin inhibitor-related kidney dysfunction.

The big picture

Eledon's progress in expanding tegoprubart's clinical applications reflects a strategic push to dominate the transplant immunosuppression market, where calcineurin inhibitors like tacrolimus have long been the standard despite significant toxicity risks. The company's ability to secure regulatory approvals and demonstrate superior outcomes in Phase 3 trials will determine its long-term competitive position in this high-stakes therapeutic area.

What we're watching

Regulatory Momentum: Whether the FDA's acceptance of the islet cell transplantation IND will accelerate tegoprubart's path to approval in multiple transplant indications.
Clinical Validation: How early data from investigator-initiated studies and compassionate use cases will influence the design and expectations for the Phase 3 LEGACY trial.
Competitive Positioning: The pace at which Eledon can differentiate tegoprubart from existing calcineurin inhibitors in terms of safety and efficacy across high-need transplant populations.